SITC Publishes Consensus Definitions for Immune Checkpoint Inhibitor-Related Adverse Events Terminology
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of several solid tumors, providing deep and durable responses for many patients. However, the anti-tumor mechanism of action of ICIs can also cause aberrantly active self-damaging immune responses, leading to immune-related adverse events (irAEs). The natural history, response to treatment, and patterns of irAEs vary widely, ranging from short-term inflammatory conditions to prolonged inflammation and damage to organs leading to permanent dysfunction.
Learn More